BioNexus Gene Lab (BGLC) Restructuring Costs (2020 - 2025)

BioNexus Gene Lab has disclosed Restructuring Costs across 6 years of filings, most recently posting $181095.0 for Q4 2025.

• Restructuring Costs for Q4 2025 came in at $181095.0, up 9.14% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.5 million (down 16.23% YoY), and the FY2025 annual result was $1.5 million, down 16.23% from the prior year.
• Restructuring Costs came in at $181095.0 for Q4 2025 at BioNexus Gene Lab, down from $445691.0 in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $3.1 million in Q3 2023 to a low of -$2.0 million in Q4 2023.
• The 5-year median for Restructuring Costs is $450231.0 (2022), against an average of $440918.4.
• Across the five-year window, Restructuring Costs soared 2894.45% in 2021 and plunged 506.52% in 2023, its largest moves.
• BioNexus Gene Lab's Restructuring Costs stood at $1.2 million in 2021, then sank by 58.01% to $487858.0 in 2022, then slumped by 506.52% to -$2.0 million in 2023, then jumped by 108.37% to $165932.0 in 2024, then increased by 9.14% to $181095.0 in 2025.
• The last three Restructuring Costs figures came in at $181095.0 (Q4 2025), $445691.0 (Q3 2025), and $516790.0 (Q2 2025), per Business Quant data.